JP4199421B2 - デキストラン−レプチン結合体、医薬組成物および関連方法 - Google Patents

デキストラン−レプチン結合体、医薬組成物および関連方法 Download PDF

Info

Publication number
JP4199421B2
JP4199421B2 JP2000564666A JP2000564666A JP4199421B2 JP 4199421 B2 JP4199421 B2 JP 4199421B2 JP 2000564666 A JP2000564666 A JP 2000564666A JP 2000564666 A JP2000564666 A JP 2000564666A JP 4199421 B2 JP4199421 B2 JP 4199421B2
Authority
JP
Japan
Prior art keywords
dextran
leptin
moiety
conjugate
moieties
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2000564666A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002522512A (ja
JP2002522512A5 (enExample
Inventor
リイツインガー，デイビツド・シー
Original Assignee
アムジエン・インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アムジエン・インコーポレーテツド filed Critical アムジエン・インコーポレーテツド
Publication of JP2002522512A publication Critical patent/JP2002522512A/ja
Publication of JP2002522512A5 publication Critical patent/JP2002522512A5/ja
Application granted granted Critical
Publication of JP4199421B2 publication Critical patent/JP4199421B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
JP2000564666A 1998-08-10 1999-08-10 デキストラン−レプチン結合体、医薬組成物および関連方法 Expired - Lifetime JP4199421B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US9619498P 1998-08-10 1998-08-10
US60/096,194 1998-08-10
US37068499A 1999-08-09 1999-08-09
US09/370,684 1999-08-09
PCT/US1999/018129 WO2000009165A1 (en) 1998-08-10 1999-08-10 Dextran-leptin conjugates, pharmaceutical compositions and related methods

Publications (3)

Publication Number Publication Date
JP2002522512A JP2002522512A (ja) 2002-07-23
JP2002522512A5 JP2002522512A5 (enExample) 2006-10-05
JP4199421B2 true JP4199421B2 (ja) 2008-12-17

Family

ID=26791397

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000564666A Expired - Lifetime JP4199421B2 (ja) 1998-08-10 1999-08-10 デキストラン−レプチン結合体、医薬組成物および関連方法

Country Status (9)

Country Link
EP (1) EP1107793B1 (enExample)
JP (1) JP4199421B2 (enExample)
AT (1) ATE280588T1 (enExample)
AU (1) AU5347099A (enExample)
CA (1) CA2337667C (enExample)
DE (1) DE69921486T2 (enExample)
ES (1) ES2228082T3 (enExample)
PT (1) PT1107793E (enExample)
WO (1) WO2000009165A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
CA2359840C (en) * 1999-02-12 2012-10-23 Amgen Inc. Glycosylated leptin compositions and related methods
GB0116860D0 (en) * 2001-07-10 2001-09-05 Univ Montfort Gel compositions
WO2005094898A2 (en) * 2004-03-23 2005-10-13 Amgen Inc. Chemically modified protein compositions and methods
US8716220B2 (en) 2005-09-07 2014-05-06 Nikolaos Tezapsidis Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amyloid beta
US8642543B2 (en) 2005-09-07 2014-02-04 Neurotez, Inc. Methods for treating progressive cognitive disorders related to neurofibrillary tangles
CN101143894A (zh) * 2007-06-22 2008-03-19 中国药科大学 高效抑制血管生成多肽及其物理化学修饰方法和应用
WO2009149379A2 (en) 2008-06-05 2009-12-10 Regents Of The University Of Michigan Use of leptin for the treatment of fatty liver diseases and conditions
MX351128B (es) 2010-09-28 2017-10-03 Aegerion Pharmaceuticals Inc Polipeptidos manipulados que tienen duracion de accion incrementada.
US9968575B2 (en) 2012-09-27 2018-05-15 The Children's Medical Center Corporation Compounds for the treatment of obesity and methods of use thereof
LT3074033T (lt) 2013-11-26 2019-02-25 The Children`S Medical Center Corporation Junginiai, skirti nutukimo gydymui ir jų panaudojimo būdai
US20170209408A1 (en) 2014-04-03 2017-07-27 The Children's Medical Center Corporation Hsp90 inhibitors for the treatment of obesity and methods of use thereof
DK3509624T3 (da) 2016-09-12 2023-11-13 Amryt Pharmaceuticals Inc Fremgangsmåder til detektering af anti-leptin-neutraliserende antistoffer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0865294B1 (en) * 1995-08-17 2004-02-18 Amgen Inc. Methods of reducing or maintaining reduced levels of blood lipids using ob protein compositions
WO1997038014A1 (en) * 1996-04-04 1997-10-16 Amgen Inc. Fibulin pharmaceutical compositions and related methods

Also Published As

Publication number Publication date
PT1107793E (pt) 2005-02-28
EP1107793A1 (en) 2001-06-20
ATE280588T1 (de) 2004-11-15
AU5347099A (en) 2000-03-06
EP1107793B1 (en) 2004-10-27
JP2002522512A (ja) 2002-07-23
CA2337667A1 (en) 2000-02-24
WO2000009165A1 (en) 2000-02-24
ES2228082T3 (es) 2005-04-01
DE69921486D1 (de) 2004-12-02
DE69921486T2 (de) 2006-02-02
CA2337667C (en) 2008-04-29

Similar Documents

Publication Publication Date Title
JP4659068B2 (ja) Ｏｂ融合タンパク質組成物および方法
EP1121155B1 (en) Site-directed dual pegylation of proteins
JP4227325B2 (ja) Ｏｂ蛋白組成物を用いる非脂肪組織重増加方法
JP4173913B2 (ja) Ｏｂタンパク質組成物を用いて血中脂質レベルを減少させ又は減少した血中脂質レベルを維持する方法
JP4199421B2 (ja) デキストラン−レプチン結合体、医薬組成物および関連方法
US20090105150A1 (en) Angiotensin derivatives
WO1997038014A1 (en) Fibulin pharmaceutical compositions and related methods
WO1998008512A1 (en) Methods of increasing sensitivity of an individual to ob protein by upregulating ob protein receptor
AU2004201326B2 (en) Dextran-Leptin Conjugates, Pharmaceutical Compositions and Related Methods
MXPA01001307A (en) Dextran-leptin conjugates, pharmaceutical compositions and related methods
KR20170069997A (ko) 미리스토일화된 렙틴-관련된 펩티드 및 이들의 용도
US7378489B1 (en) Angiotensin derivatives
AU2006201747B2 (en) Methods of Increasing Lean Tissue Mass Using OB Protein Compositions
AU2004200516B2 (en) Methods of Increasing Lean Tissue Mass Using OB Protein Compositions
AU2003201360B2 (en) Methods of Reducing or Maintaining Reduced Levels of Blood Lipids Using OB Protein Compositions
MXPA01003764A (en) Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
HK1022438A (en) Methods of increasing lean tissue mass using ob protein compositions

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060807

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060807

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20061024

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20070117

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20070125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070423

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20080205

RD13 Notification of appointment of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7433

Effective date: 20080205

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080513

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080812

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20080909

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20081003

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20111010

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 4199421

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121010

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121010

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131010

Year of fee payment: 5

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term